In July 2018, the FDA recalled certain batches of valsartan after investigators found N-Nitrosimethylamine (NDMA) had contaminated the drug. Since then, several batches of valsartan, irbesartan, and losartan have been recalled due to NDMA and N-Nitrosodiethylamine (NDEA) contamination. These nitrosamines are classified as probable human carcinogens.
How Are They Similar?
NDMA and NDEA are both classified by the Environmental Protection Agency as probable human carcinogens. Exposure to these carcinogens can cause tumors to develop in the respiratory tract. Specifically, an individual may develop liver, stomach, colorectal, pancreatic, prostate, esophageal, and/or intestinal cancer. Exposure has also been linked to non-hodgkin’s lymphoma, leukemia, and multiple myeloma.
What’s the Difference?
The main difference between NDMA and NDEA is toxicity. NDEA happens to be about three times more toxic than NDMA.
What Should I Do?
If you or a loved one took a recalled valsartan, irbesartan, or losartan and developed prostate cancer (before age 60), lower esophageal cancer, non-hodgkins lymphoma, leukemia, multiple myeloma, colon, stomach, intestinal, or pancreatic cancer, please fill out the form below. We deliver the Gold standard advocacy you deserve.